← Eichor
Study identifier: NCT05331105 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Condition: Neurofibromatosis 1 · Plexiform Neurofibromas  ·  Sponsor: Shanghai Kechow Pharma, Inc.

PhasePhase 2
Planned participants70
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)

This description comes directly from the study's public registry record.

Talk to the study team

Zhimei Zhu, Master  ·  86 215201345822  ·  zhuzm@kechowpharma.com

Hongqi Tian, Ph.D  ·  tianhq@kechowpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05331105